



# EXHIBIT A

United States  
National Library  
of Medicine

ChemIDplus Lite



News

[SIS Home](#) | [Site](#) | [About Us](#) | [Contact](#)**Full Record****Verteporfin [USAN:INN]  
RN: 129497-78-5****Structure  
Descriptors****InChI**

InChI=1/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1

[Download](#) | [View Full InChI](#)**Smiles**

C=1(CCC(OC)=O)c2cc3c(c(c(cc4nc(cc5C=6[C@@@]([C@@H](C(=CC6)C(OC)=O)C(=O)OC)(c([nH]5)cc(n2)C1C)C)C(C)=C4C=C)[nH]3)C)CCC(O)=O

[Download](#)**Names and  
Synonyms****Name of Substance**

[i](#) Verteporfin  
[i](#) Verteporfin [USAN:INN]

**Synonyms**


[i](#) (+)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester mixture with (+)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester  
[i](#) CL 318,952  
[i](#) UNII-0X9PA28K43  
[i](#) Verteporfin  
[i](#) Visudyne

**Systematic Name**


[i](#) 23H,25H-Benzo(b)porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-

tetramethyl-, monomethyl ester, trans-





**Registry  
Numbers****CAS Registry Number**

 129497-78-5


**System Generated Number**

 0129497785

**Classification  
Codes****Classification Code**

-  Antineoplastic
-  Dermatologic Agents
-  Photosensitizing agents
-  Radiation-Sensitizing Agents











**Formulas****Molecular Formula**

 C41-H42-N4-O8





**Notes****Note**

 Used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION.

**Locators****File Locator**

- |                    |  |
|--------------------|--|
| ClinicalTrials.gov |  NIH ClinicalTrials.gov           |
| DailyMed           |  NLM/FDA Drug Labelling           |
| MeSH               |  Medical Subject Headings File    |
| PubChem            |  PubChem                          |
| PubMed AIDS        |  AIDS Citations from PubMed       |
| PubMed Cancer      |  Cancer Citations from PubMed     |
| PubMed Toxicology  |  Toxicology Citations From PubMed |
| PubMed             |  Biomedical Citations From PubMed |
| TOXLINE            |  NLM TOXLINE on TOXNET            |
| MedlinePlusAll     |  Search Consumer Health Info      |

**Internet Locator**


- |            |   |
|------------|---|
| CTD        |  Comparative Toxicogenomics Database |
| DrugDigest |  Drug Digest                         |
| Drugs@FDA  |  FDA Drug Database                   |
| USA.gov    |  USA.gov Search Engine               |

---

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894,  
National Institutes of Health, Department of Health & Human Services  
Copyright and Privacy Policy, Freedom of Information Act, Accessibility  
Customer Service: [tehip@tehl.nlm.nih.gov](mailto:tehip@tehl.nlm.nih.gov).

United States  
National Library  
of Medicine

ChemIDplus Lite

[News](#)[SIS Home](#) | [Site](#) | [About Us](#) | [Contact](#)**Full Record****Ranibizumab [USAN]  
RN: 347396-82-1****No Structure**

---


**Structure  
Descriptors**

No descriptors found for this chemical.











---

**Names and  
Synonyms****Name of Substance****i** Ranibizumab [USAN]**Synonyms****i** Lucentis**i** Ranibizumab**i** UNII-ZL1R02VT79**i** rhuFab V2**Systematic Name****i** Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1 chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain**Registry  
Numbers****CAS Registry Number****i** 347396-82-1**System Generated Number****i** 0347396821**Classification  
Codes****Classification Code****i** Treatment of age-related macular degeneration




**Formulas**      **Molecular Formula**  
 Unspecified

**Notes**      **Note**  
 Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration

**Locators**      **File Locator**

ClinicalTrials.gov	 NIH ClinicalTrials.gov
DailyMed	 NLM/FDA Drug Labelling
MedlinePlusDrug	 Consumer Drug Information
MeSH	 Medical Subject Headings File
PubMed AIDS	 AIDS Citations from PubMed
PubMed Cancer	 Cancer Citations from PubMed
PubMed Toxicology	 Toxicology Citations From PubMed
PubMed	 Biomedical Citations From PubMed
TOXLINE	 NLM TOXLINE on TOXNET
MedlinePlusAll	 Search Consumer Health Info

**Internet Locator**


DrugDigest	 Drug Digest
Drugs@FDA	 FDA Drug Database
USA.gov	 USA.gov Search Engine

---

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894,  
National Institutes of Health, Department of Health & Human Services  
Copyright and Privacy Policy, Freedom of Information Act, Accessibility  
Customer Service: [tehip@tehl.nlm.nih.gov](mailto:tehip@tehl.nlm.nih.gov).

United States  
National Library  
of Medicine

ChemIDplus Lite

[News](#)[SIS Home](#) | [Site](#) | [About Us](#) | [Contact](#)**Full Record****Pegaptanib sodium [USAN]**  
**RN: 222716-86-1****Structure  
Descriptors****InChI**

InChI=1S/C20H40N3O10P.Na/c1-29-13-15-31-19(25)22-11-7-5-9-17(23-20(26)32-16-14-30-2)18  
(24)21-10-6-4-8-12-33-34(3,27)28;/h17H,4-16H2,1-3H3,(H,21,24)(H,22,25)(H,23,26)  
(H,27,28);/q;+1/p-1/t17-;/m0./s1

[Download](#) | [View Full InChI](#)**Names and  
Synonyms****Name of Substance****[i]** Pegaptanib sodium [USAN]**Synonyms**

**[i]** 5'-Ester of (2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'-3')-dT with alpha, alpha'-(((1S)-1-((5-(phosphonoxy)pentyl)carbamoyl)pentane-1,5-diyl)bis(iminocarbonyl))bis(omega-methoxypoly(oxyethane-1,2-diyl)) octacosasodium salt. Molecular weight is approximately 50,000 daltons

**[i]** EYE 001**[i]** EYE001**[i]** Macugen**[i]** NX 1838**[i]** NX1838**[i]** Pegaptanib octasodium**[i]** Pegaptanib sodium**[i]** UNII-3HP012Q0FH

**Systematic Name**

**i** RNA, ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'-3')-dT), 5'-ester with alpha, alpha'-(4,12-dioxo-6-(((5-(phosphonoxy)pentyl)amino)carbonyl)-3,13-dioxo-5,11-diaza-1,15-pentadecanediyl)bis(omega-methoxypoly(oxy-1,2-ethanediyl))), sodium salt

**Registry Numbers****CAS Registry Number**

**i** 222716-86-1

**Other Registry Number**

**i** 250689-71-5

**System Generated Number**

**i** 0222716861

**Classification Codes****Classification Code**

**i** Treatment of age-related macular degeneration disease [anti-VEGF aptamer]

**Formulas****Molecular Formula**

**i** C294-H342-F13-N107-Na28-O188-P28-(C2-H4-O)<sub>n</sub>

**i** Unspecified

**Notes****Note**

**i** A 28-base ribonucleic acid aptamer covalently linked to two branched 20-kD polyethylene glycol moieties to block the activity of extracellular VEGF, specifically the 165-amino-acid isoform (VEGF165); for treatment of neovascular age-related macular degeneration.

**Locators****File Locator**

ClinicalTrials.gov

**i** NIH ClinicalTrials.gov

DailyMed

**i** NLM/FDA Drug Labelling

MedlinePlusDrug

**i** Consumer Drug Information

MeSH

**i** Medical Subject Headings File

PubChem

**i** PubChem

PubMed

**i** Biomedical Citations From PubMed

PubMed AIDS

**i** AIDS Citations from PubMed

PubMed Toxicology

**i** Toxicology Citations From PubMed

TOXLINE

**i** NLM TOXLINE on TOXNET

MedlinePlusAll

**i** Search Consumer Health Info

**Internet Locator**


DrugDigest

**i** Drug Digest

Drugs@FDA

**i** FDA Drug Database

USA.gov

 USA.gov Search Engine

---

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894,  
National Institutes of Health, Department of Health & Human Services  
Copyright and Privacy Policy, Freedom of Information Act, Accessibility  
Customer Service: [tehip@tehl.nlm.nih.gov](mailto:tehip@tehl.nlm.nih.gov).